|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNF8 |
Gene summary for SNF8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNF8 | Gene ID | 11267 |
| Gene name | SNF8 subunit of ESCRT-II | |
| Gene Alias | Dot3 | |
| Cytomap | 17q21.32 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96H20 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11267 | SNF8 | P23T-E | Human | Esophagus | ESCC | 1.68e-41 | 9.79e-01 | 0.108 |
| 11267 | SNF8 | P24T-E | Human | Esophagus | ESCC | 1.52e-39 | 9.73e-01 | 0.1287 |
| 11267 | SNF8 | P26T-E | Human | Esophagus | ESCC | 3.49e-50 | 9.39e-01 | 0.1276 |
| 11267 | SNF8 | P27T-E | Human | Esophagus | ESCC | 1.16e-31 | 5.54e-01 | 0.1055 |
| 11267 | SNF8 | P28T-E | Human | Esophagus | ESCC | 3.55e-40 | 9.24e-01 | 0.1149 |
| 11267 | SNF8 | P30T-E | Human | Esophagus | ESCC | 1.32e-19 | 7.01e-01 | 0.137 |
| 11267 | SNF8 | P31T-E | Human | Esophagus | ESCC | 2.21e-43 | 8.07e-01 | 0.1251 |
| 11267 | SNF8 | P32T-E | Human | Esophagus | ESCC | 6.15e-49 | 1.10e+00 | 0.1666 |
| 11267 | SNF8 | P36T-E | Human | Esophagus | ESCC | 4.36e-26 | 8.71e-01 | 0.1187 |
| 11267 | SNF8 | P37T-E | Human | Esophagus | ESCC | 8.05e-42 | 8.89e-01 | 0.1371 |
| 11267 | SNF8 | P38T-E | Human | Esophagus | ESCC | 2.97e-23 | 7.46e-01 | 0.127 |
| 11267 | SNF8 | P39T-E | Human | Esophagus | ESCC | 1.38e-23 | 5.13e-01 | 0.0894 |
| 11267 | SNF8 | P40T-E | Human | Esophagus | ESCC | 1.63e-21 | 6.83e-01 | 0.109 |
| 11267 | SNF8 | P42T-E | Human | Esophagus | ESCC | 3.39e-24 | 5.83e-01 | 0.1175 |
| 11267 | SNF8 | P44T-E | Human | Esophagus | ESCC | 2.51e-19 | 5.15e-01 | 0.1096 |
| 11267 | SNF8 | P47T-E | Human | Esophagus | ESCC | 6.78e-52 | 9.70e-01 | 0.1067 |
| 11267 | SNF8 | P48T-E | Human | Esophagus | ESCC | 4.96e-19 | 4.75e-01 | 0.0959 |
| 11267 | SNF8 | P49T-E | Human | Esophagus | ESCC | 1.92e-11 | 1.46e+00 | 0.1768 |
| 11267 | SNF8 | P52T-E | Human | Esophagus | ESCC | 7.21e-54 | 1.01e+00 | 0.1555 |
| 11267 | SNF8 | P54T-E | Human | Esophagus | ESCC | 3.43e-20 | 4.02e-01 | 0.0975 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
| GO:0042176 | Colorectum | AD | regulation of protein catabolic process | 160/3918 | 391/18723 | 1.06e-19 | 7.34e-17 | 160 |
| GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
| GO:0019058 | Colorectum | AD | viral life cycle | 119/3918 | 317/18723 | 6.18e-12 | 8.23e-10 | 119 |
| GO:0072594 | Colorectum | AD | establishment of protein localization to organelle | 148/3918 | 422/18723 | 7.95e-12 | 1.04e-09 | 148 |
| GO:0045732 | Colorectum | AD | positive regulation of protein catabolic process | 92/3918 | 231/18723 | 3.85e-11 | 4.47e-09 | 92 |
| GO:0016197 | Colorectum | AD | endosomal transport | 90/3918 | 230/18723 | 1.88e-10 | 1.73e-08 | 90 |
| GO:0016482 | Colorectum | AD | cytosolic transport | 68/3918 | 168/18723 | 6.00e-09 | 3.72e-07 | 68 |
| GO:0016236 | Colorectum | AD | macroautophagy | 103/3918 | 291/18723 | 6.76e-09 | 4.15e-07 | 103 |
| GO:0098876 | Colorectum | AD | vesicle-mediated transport to the plasma membrane | 57/3918 | 136/18723 | 2.30e-08 | 1.27e-06 | 57 |
| GO:1990182 | Colorectum | AD | exosomal secretion | 16/3918 | 20/18723 | 2.67e-08 | 1.47e-06 | 16 |
| GO:0097734 | Colorectum | AD | extracellular exosome biogenesis | 16/3918 | 21/18723 | 9.02e-08 | 4.52e-06 | 16 |
| GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
| GO:0007034 | Colorectum | AD | vacuolar transport | 60/3918 | 157/18723 | 4.97e-07 | 1.85e-05 | 60 |
| GO:0140112 | Colorectum | AD | extracellular vesicle biogenesis | 16/3918 | 23/18723 | 7.04e-07 | 2.49e-05 | 16 |
| GO:1903541 | Colorectum | AD | regulation of exosomal secretion | 13/3918 | 17/18723 | 1.46e-06 | 4.58e-05 | 13 |
| GO:0050792 | Colorectum | AD | regulation of viral process | 59/3918 | 164/18723 | 5.95e-06 | 1.52e-04 | 59 |
| GO:1903543 | Colorectum | AD | positive regulation of exosomal secretion | 11/3918 | 15/18723 | 1.95e-05 | 4.01e-04 | 11 |
| GO:0036257 | Colorectum | AD | multivesicular body organization | 17/3918 | 31/18723 | 3.45e-05 | 6.29e-04 | 17 |
| GO:0071985 | Colorectum | AD | multivesicular body sorting pathway | 19/3918 | 37/18723 | 4.08e-05 | 7.26e-04 | 19 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041442 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
| hsa041443 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
| hsa041444 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa041445 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414412 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414413 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa0414428 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
| hsa0414436 | Oral cavity | LP | Endocytosis | 121/2418 | 251/8465 | 1.89e-11 | 3.70e-10 | 2.38e-10 | 121 |
| hsa0414425 | Prostate | BPH | Endocytosis | 89/1718 | 251/8465 | 1.06e-08 | 1.29e-07 | 7.99e-08 | 89 |
| hsa04144111 | Prostate | BPH | Endocytosis | 89/1718 | 251/8465 | 1.06e-08 | 1.29e-07 | 7.99e-08 | 89 |
| hsa0414426 | Prostate | Tumor | Endocytosis | 92/1791 | 251/8465 | 7.83e-09 | 1.04e-07 | 6.43e-08 | 92 |
| hsa0414435 | Prostate | Tumor | Endocytosis | 92/1791 | 251/8465 | 7.83e-09 | 1.04e-07 | 6.43e-08 | 92 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SNF8 | SNV | Missense_Mutation | c.52N>C | p.Glu18Gln | p.E18Q | Q96H20 | protein_coding | tolerated(1) | benign(0.084) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| SNF8 | SNV | Missense_Mutation | c.171N>C | p.Glu57Asp | p.E57D | Q96H20 | protein_coding | tolerated(0.87) | benign(0.005) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SNF8 | SNV | Missense_Mutation | c.39N>T | p.Lys13Asn | p.K13N | Q96H20 | protein_coding | tolerated(0.3) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SNF8 | SNV | Missense_Mutation | c.594N>G | p.Ile198Met | p.I198M | Q96H20 | protein_coding | deleterious(0) | possibly_damaging(0.572) | TCGA-C8-A278-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| SNF8 | deletion | Frame_Shift_Del | novel | c.691delN | p.Glu231ArgfsTer95 | p.E231Rfs*95 | Q96H20 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| SNF8 | deletion | Frame_Shift_Del | novel | c.578delT | p.Val193GlyfsTer25 | p.V193Gfs*25 | Q96H20 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| SNF8 | SNV | Missense_Mutation | novel | c.494N>A | p.Gly165Asp | p.G165D | Q96H20 | protein_coding | tolerated(0.08) | possibly_damaging(0.658) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SNF8 | SNV | Missense_Mutation | c.295N>A | p.Glu99Lys | p.E99K | Q96H20 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SNF8 | SNV | Missense_Mutation | c.350G>C | p.Gly117Ala | p.G117A | Q96H20 | protein_coding | deleterious(0) | benign(0.158) | TCGA-DM-A1D4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| SNF8 | SNV | Missense_Mutation | c.170N>T | p.Glu57Val | p.E57V | Q96H20 | protein_coding | deleterious(0) | possibly_damaging(0.514) | TCGA-F5-6702-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | oxaliplatin | PD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |